Cargando…

Cost-effectiveness analysis of genotype screening and therapeutic drug monitoring in patients with inflammatory bowel disease treated with azathioprine therapy: a Chinese healthcare perspective using real-world data

BACKGROUND: This study aimed to analyze the cost-effectiveness of combining screening for thiopurine methyl transferase (TPMT) and nucleotide triphosphate diphosphatase (NUDT15) defective alleles with therapeutic drug monitoring (TDM) in Chinese patients with inflammatory bowel disease (IBD) treated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zeng, Dayong, Huang, Xiaoting, Lin, Shen, Lin, Rongfang, Weng, Xiuhua, Huang, Pinfang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350671/ https://www.ncbi.nlm.nih.gov/pubmed/34430579 http://dx.doi.org/10.21037/atm-21-1980

Ejemplares similares

Half-dose fulvestrant plus anastrozole as a first-line treatment for hormone receptor-positive metastatic breast cancer: a cost-effectiveness analysis
por: Huang, Xiaoting, et al.
Publicado: (2020)

Real-World Use of Azathioprine Metabolites Changes Clinical Management of Inflammatory Bowel Disease
por: Wilson, Laura, et al.
Publicado: (2020)

Monitoring and Safety of Azathioprine Therapy in Inflammatory Bowel Disease
por: Kim, Mi Jin, et al.
Publicado: (2013)

Long‐term safety and effectiveness of azathioprine in the management of inflammatory bowel disease: A real‐world experience
por: Yewale, Rohan V, et al.
Publicado: (2023)

Preemptive TPMT Genotyping and Adherence to Genotype-Based Therapeutic Recommendations Reduces the Healthcare Cost in Patients Receiving Azathioprine or 6-Mercaptopurine for Autoimmune Diseases
por: Valdez-Acosta, Sarahí, et al.
Publicado: (2023)

Cost–Utility Analysis of Pembrolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer With Different PD-L1 Expression Levels
por: Weng, Xiuhua, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Hepatic Arterial Infusion of FOLFOX Combined Sorafenib for Advanced Hepatocellular Carcinoma With Portal Vein Invasion
por: Li, Meiyue, et al.
Publicado: (2021)

Azathioprine in inflammatory bowel disease, a safe alternative?
por: Tanis, A A
Publicado: (1998)

Implementation of NUDT15 Genotyping to Prevent Azathioprine‐Induced Leukopenia for Patients With Autoimmune Disorders in Chinese Population
por: Wang, Chuang‐Wei, et al.
Publicado: (2022)

NUDT15 genotyping during azathioprine treatment in patients with inflammatory bowel disease: implications for a dose-optimization strategy
por: Xu, Ye, et al.
Publicado: (2020)

Thalidomide Combined With Azathioprine as Induction and Maintenance Therapy for Azathioprine-Refractory Crohn's Disease Patients
por: Li, Tong, et al.
Publicado: (2020)

Successful Azathioprine Treatment with Metabolite Monitoring in a Pediatric Inflammatory Bowel Disease Patient Homozygous for TPMT(*)3C
por: Lee, Mi-Na, et al.
Publicado: (2013)

Application of Physiologically Based Pharmacokinetic Modeling to Predict Maternal Pharmacokinetics and Fetal Exposure to Oxcarbazepine
por: He, Lixia, et al.
Publicado: (2022)

Low-dose azathioprine effectively improves mucosal healing in Chinese patients with small bowel Crohn's disease
por: Yu, Li Fen, et al.
Publicado: (2014)

Awareness of adverse effects of Azathioprine in patients with Inflammatory Bowel Disease – more to be done?
por: Spence, Andrew David Roy, et al.
Publicado: (2014)

Azathioprine with Allopurinol Is a Promising First-Line Therapy for Inflammatory Bowel Diseases
por: van Liere, Elsa L. S. A., et al.
Publicado: (2021)

Real‐world utilization and healthcare costs for multiple myeloma: A retrospective analysis of patients in Singapore
por: Bayani, Diana Beatriz, et al.
Publicado: (2023)

Chronic Genotype 3 Hepatitis E in Pregnant Woman Receiving Infliximab and Azathioprine
por: Charre, Caroline, et al.
Publicado: (2018)

The Predictive Value of PD-L1 Expression Level in Evaluating the Cost-Effectiveness of Atezolizumab/Pembrolizumab
por: Lin, Shen, et al.
Publicado: (2022)

Prospective Evaluation of Pharmacogenomics and Metabolite Measurements upon Azathioprine Therapy in Inflammatory Bowel Disease: An Observational Study
por: Fangbin, Zhang, et al.
Publicado: (2016)

Azathioprine Hypersensitivity Syndrome: Two Cases of Febrile Neutrophilic Dermatosis Induced by Azathioprine
por: Aleissa, Majed, et al.
Publicado: (2017)

C-reactive protein levels and prevalence of leukopenia in patients with inflammatory bowel disease treated with azathioprine and/or mesalazine: a real-life study
por: dos Santos, Rejani Cristine Faustino, et al.
Publicado: (2022)

Change in Hematologic Indices over Time in Pediatric Inflammatory Bowel Disease Treated with Azathioprine
por: Soman, Sherman, et al.
Publicado: (2012)

Adverse Events Associated with Azathioprine Treatment in Korean Pediatric Inflammatory Bowel Disease Patients
por: Chun, Ji Young, et al.
Publicado: (2013)

The Impact of Azathioprine-Associated Lymphopenia on the Onset of Opportunistic Infections in Patients with Inflammatory Bowel Disease
por: Vögelin, Marius, et al.
Publicado: (2016)

Azathioprine monotherapy withdrawal in inflammatory bowel diseases: A retrospective mono-centric study
por: Crepaldi, Martina, et al.
Publicado: (2023)

Analysis of the NUDT15 gene and metabolites of azathioprine in Japanese patients with inflammatory bowel disease
por: Suzuki, Shizuka, et al.
Publicado: (2023)

Commensal bacteria promote azathioprine therapy failure in inflammatory bowel disease via decreasing 6-mercaptopurine bioavailability
por: Yan, Yuqing, et al.
Publicado: (2023)

Prophylaxis for Pneumocystis carinii pneumonia in non-Hodgkin’s lymphoma undergoing R-CHOP21 in China: a meta-analysis and cost-effectiveness analysis
por: Huang, Xiaojia, et al.
Publicado: (2023)

Adherence to Azathioprine/6-Mercaptopurine in Children and Adolescents with Inflammatory Bowel Diseases: A Multimethod Study
por: Alsous, Mervat M., et al.
Publicado: (2020)

Usefulness of Measuring Thiopurine Metabolites in Children with Inflammatory Bowel Disease and Autoimmunological Hepatitis, Treated with Azathioprine
por: Bąk-Drabik, Katarzyna, et al.
Publicado: (2021)

Infection risk in sarcoidosis patients treated with methotrexate compared to azathioprine: A retrospective ‘target trial’ emulated with Swedish real‐world data
por: Rossides, Marios, et al.
Publicado: (2021)

The adverse effect profile of oral azathioprine in pediatric atopic dermatitis, and recommendations for monitoring
por: Fuggle, Nicholas R., et al.
Publicado: (2015)

Azathioprine induced cholestatic hepatitis
por: Moses, Viju, et al.
Publicado: (2011)

Azathioprine: its uses in dermatology()()
por: Chavez-Alvarez, Sonia, et al.
Publicado: (2020)

Azathioprine-Induced Hypersensitivity Vasculitis
por: Sangiorgio, Michael, et al.
Publicado: (2023)

Azathioprine with Allopurinol: Lower Deoxythioguanosine in DNA and Transcriptome Changes Indicate Mechanistic Differences to Azathioprine Alone
por: Coulthard, Sally A., et al.
Publicado: (2017)

Azathioprine-induced Acute Pancreatitis in Patients with Inflammatory Bowel Diseases—A Prospective Study on Incidence and Severity
por: Teich, Niels, et al.
Publicado: (2016)

Azathioprine is More Effective than Mesalazine at Preventing Recurrent Bowel Obstruction in Patients with Ileocecal Crohn’s Disease
por: Vidigal, Fernando Mendonça, et al.
Publicado: (2014)

Azathioprine dosing and metabolite measurement in pediatric inflammatory bowel disease: does one size fit all?
por: Walker, Rebecca, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_oiumk09edu91bp48kigkqa6jk6